- Previous Close
51.62 - Open
52.81 - Bid 53.80 x --
- Ask 53.82 x --
- Day's Range
50.70 - 53.85 - 52 Week Range
30.43 - 60.54 - Volume
10,490,931 - Avg. Volume
10,162,534 - Market Cap (intraday)
22.515B - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
49.36 - EPS (TTM)
1.09 - Earnings Date --
- Forward Dividend & Yield 0.17 (0.33%)
- Ex-Dividend Date Jun 6, 2024
- 1y Target Est
50.70
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. The company was founded in 2003 and is headquartered in Hangzhou, China.
www.bettapharma.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 300558.SZ
View MorePerformance Overview: 300558.SZ
Trailing total returns as of 11/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300558.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300558.SZ
View MoreValuation Measures
Market Cap
21.60B
Enterprise Value
23.11B
Trailing P/E
47.36
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.89
Price/Book (mrq)
3.83
Enterprise Value/Revenue
8.38
Enterprise Value/EBITDA
45.64
Financial Highlights
Profitability and Income Statement
Profit Margin
16.67%
Return on Assets (ttm)
2.80%
Return on Equity (ttm)
8.03%
Revenue (ttm)
2.76B
Net Income Avi to Common (ttm)
459.57M
Diluted EPS (ttm)
1.09
Balance Sheet and Cash Flow
Total Cash (mrq)
816.38M
Total Debt/Equity (mrq)
40.67%
Levered Free Cash Flow (ttm)
-164.48M